AOC-1044 is under clinical development by Avidity Biosciences and currently in Phase II for Duchenne Muscular Dystrophy. According to GlobalData, Phase II drugs for Duchenne Muscular Dystrophy have a 61% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AOC-1044’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AOC-1044 overview

AOC-1044 is under development for the treatment of Duchenne muscular dystrophy. The drug candidate is an antibody oligonucleotide conjugate (AOC) comprising monoclonal antibody that binds to the transferrin receptor 1 (TfR1) conjugated with phosphorodiamidate morpholino oligomer (PMO) targeting exon 44 of dystrophin mRNA. It is being developed based on antibody oligonucleotide conjugate (AOC) platform.

Avidity Biosciences overview

Avidity Biosciences is a biotech company that develops antibody oligonucleotide conjugates (AOCs). The company product pipeline include AOC 1001, AOC 1044 and AOC 1020. Its pipeline treats myotonic dystrophy type 1 (DM1), duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity Biosciences carries out AOC components such as monoclonal, linker, siRNA and PMO. The company has research collaborations with leading pharma companies, to discover antibody-based drug candidates against various therapeutic targets. Avidity Biosciences is headquartered in San Diego, California, the US.

For a complete picture of AOC-1044’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.